At the time of writing, Denali Therapeutics Inc [DNLI] stock is trading at $23.30, down -1.19%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DNLI shares have gain 4.86% over the last week, with a monthly amount glided 15.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on January 07, 2025, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $31. On December 16, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $37 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Citigroup started tracking with a Buy rating for this stock on December 13, 2023, and assigned it a price target of $32.
For the past year, the stock price of Denali Therapeutics Inc fluctuated between $14.56 and $33.33. Currently, Wall Street analysts expect the stock to reach $34.5 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $23.30 at the most recent close of the market. An investor can expect a potential return of 48.07% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
According to Denali Therapeutics Inc [NASDAQ:DNLI], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 1.02% with Operating Profit Margin at 1.65%, Pretax Profit Margin comes in at 1.4%, and Net Profit Margin reading is 1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.75 points at the first support level, and at 22.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.83, and for the 2nd resistance point, it is at 24.36.
Ratios To Look Out For
It is important to note that Denali Therapeutics Inc [NASDAQ:DNLI] has a current ratio of 9.98. As well, the Quick Ratio is 9.98, while the Cash Ratio is 1.04.
Transactions by insiders
Recent insider trading involved Ho Carole, Chief Medical Officer, that happened on Jan 06 ’25 when 12255.0 shares were sold. Chief Medical Officer, Ho Carole completed a deal on Jan 07 ’25 to sell 2907.0 shares. Meanwhile, COFO and Secretary Schuth Alexander O. sold 12255.0 shares on Jan 06 ’25.
